Ionis Historical Income Statement

IONS Stock

USD 35.46 1.45 4.26%

Historical analysis of Ionis Pharmaceuticals income statement accounts such as Total Revenue of 827 M or Gross Profit of 817.4 M can show how well Ionis Pharmaceuticals performed in making a profits. Evaluating Ionis Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ionis Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Ionis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ionis Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

About Ionis Income Statement Analysis

Ionis Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ionis Pharmaceuticals shareholders. The income statement also shows Ionis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Ionis Pharmaceuticals Income Statement Chart

At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 244.2 M in 2024, despite the fact that EBIT is likely to grow to (239.9 M).

Total Revenue Other Operating Expenses Cost Of Revenue Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Ionis Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ionis Pharmaceuticals. It is also known as Ionis Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Ionis Pharmaceuticals income statement and represents the costs associated with goods and services Ionis Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Ionis Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 244.2 M in 2024, despite the fact that EBIT is likely to grow to (239.9 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	829M	984M	779.6M	818.6M
Cost Of Revenue	11M	14M	9.1M	8.7M

Total Operating Expenses Cost Of Revenue

Ionis Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Net Income	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Research Development	Selling General Administrative	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.5	0.76	0.78	0.92	-0.53	-0.41	-0.37	-0.49	0.87	-0.47	-0.45	0.39	0.23	0.93	0.66	-0.46	-0.44	0.8	-0.6	0.22	-0.61	-0.2	0.9	0.85
Interest Expense	0.5		0.57	0.48	0.62	-0.24	-0.2	-0.19	-0.04	0.44	-0.29	-0.32	-0.18	0.11	0.59	0.57	-0.3	-0.28	0.59	-0.45	0.09	-0.07	-0.88	0.36	0.47
Total Revenue	0.76	0.57		0.95	0.87	0.01	0.12	0.16	-0.4	0.89	-0.06	0.06	0.03	0.19	0.78	0.89	-0.21	-0.03	0.51	-0.78	0.17	-0.4	-0.25	0.78	0.87
Gross Profit	0.78	0.48	0.95		0.86	-0.06	0.06	0.09	-0.67	0.87	-0.08	0.01	0.08	0.18	0.76	0.91	-0.32	-0.07	0.56	-0.78	0.16	-0.59	-0.23	0.86	0.95
Other Operating Expenses	0.92	0.62	0.87	0.86		-0.48	-0.37	-0.33	-0.45	0.95	-0.44	-0.42	0.33	0.23	0.98	0.83	-0.52	-0.43	0.81	-0.78	0.21	-0.48	-0.3	0.92	0.92
Operating Income	-0.53	-0.24	0.01	-0.06	-0.48		0.98	0.97	0.2	-0.35	0.79	0.98	-0.65	-0.12	-0.59	-0.1	0.69	0.81	-0.75	0.19	-0.12	0.28	0.16	-0.49	-0.32
Ebit	-0.41	-0.2	0.12	0.06	-0.37	0.98		1.0	0.13	-0.24	0.79	0.99	-0.53	-0.11	-0.47	-0.05	0.56	0.82	-0.61	0.15	-0.11	0.18	0.16	-0.36	-0.21
Ebitda	-0.37	-0.19	0.16	0.09	-0.33	0.97	1.0		0.11	-0.21	0.78	0.99	-0.53	-0.11	-0.43	-0.02	0.55	0.81	-0.59	0.13	-0.1	0.16	0.16	-0.32	-0.18
Cost Of Revenue	-0.49	-0.04	-0.4	-0.67	-0.45	0.2	0.13	0.11		-0.42	0.11	0.11	-0.17	-0.07	-0.38	-0.56	0.45	0.14	-0.45	0.43	-0.06	0.79	0.08	-0.64	-0.71
Total Operating Expenses	0.87	0.44	0.89	0.87	0.95	-0.35	-0.24	-0.21	-0.42		-0.32	-0.26	0.39	0.23	0.9	0.85	-0.34	-0.3	0.65	-0.84	0.21	-0.44	-0.05	0.9	0.91
Net Income	-0.47	-0.29	-0.06	-0.08	-0.44	0.79	0.79	0.78	0.11	-0.32		0.8	-0.29	-0.68	-0.49	-0.2	0.5	1.0	-0.59	0.08	-0.68	0.29	0.24	-0.43	-0.23
Income Before Tax	-0.45	-0.32	0.06	0.01	-0.42	0.98	0.99	0.99	0.11	-0.26	0.8		-0.49	-0.11	-0.53	-0.07	0.61	0.83	-0.68	0.16	-0.11	0.17	0.27	-0.39	-0.24
Total Other Income Expense Net	0.39	-0.18	0.03	0.08	0.33	-0.65	-0.53	-0.53	-0.17	0.39	-0.29	-0.49		-0.13	0.43	0.02	-0.54	-0.3	0.53	-0.19	-0.13	-0.25	0.37	0.43	0.28
Income Tax Expense	0.23	0.11	0.19	0.18	0.23	-0.12	-0.11	-0.11	-0.07	0.23	-0.68	-0.11	-0.13		0.18	0.29	-0.07	-0.65	0.14	0.0	1.0	-0.27	-0.08	0.26	0.12
Research Development	0.93	0.59	0.78	0.76	0.98	-0.59	-0.47	-0.43	-0.38	0.9	-0.49	-0.53	0.43	0.18		0.69	-0.62	-0.48	0.87	-0.67	0.16	-0.45	-0.28	0.91	0.85
Selling General Administrative	0.66	0.57	0.89	0.91	0.83	-0.1	-0.05	-0.02	-0.56	0.85	-0.2	-0.07	0.02	0.29	0.69		-0.23	-0.2	0.5	-0.88	0.27	-0.46	-0.33	0.75	0.9
Selling And Marketing Expenses	-0.46	-0.3	-0.21	-0.32	-0.52	0.69	0.56	0.55	0.45	-0.34	0.5	0.61	-0.54	-0.07	-0.62	-0.23		0.53	-0.86	0.19	-0.06	0.41	0.33	-0.61	-0.45
Net Income From Continuing Ops	-0.44	-0.28	-0.03	-0.07	-0.43	0.81	0.82	0.81	0.14	-0.3	1.0	0.83	-0.3	-0.65	-0.48	-0.2	0.53		-0.59	0.11	-0.65	0.28	0.25	-0.43	-0.23
Non Operating Income Net Other	0.8	0.59	0.51	0.56	0.81	-0.75	-0.61	-0.59	-0.45	0.65	-0.59	-0.68	0.53	0.14	0.87	0.5	-0.86	-0.59		-0.44	0.13	-0.5	-0.46	0.79	0.69
Minority Interest	-0.6	-0.45	-0.78	-0.78	-0.78	0.19	0.15	0.13	0.43	-0.84	0.08	0.16	-0.19	0.0	-0.67	-0.88	0.19	0.11	-0.44		0.02	0.22	0.16	-0.68	-0.82
Tax Provision	0.22	0.09	0.17	0.16	0.21	-0.12	-0.11	-0.1	-0.06	0.21	-0.68	-0.11	-0.13	1.0	0.16	0.27	-0.06	-0.65	0.13	0.02		-0.27	-0.08	0.24	0.1
Interest Income	-0.61	-0.07	-0.4	-0.59	-0.48	0.28	0.18	0.16	0.79	-0.44	0.29	0.17	-0.25	-0.27	-0.45	-0.46	0.41	0.28	-0.5	0.22	-0.27		0.06	-0.67	-0.65
Net Interest Income	-0.2	-0.88	-0.25	-0.23	-0.3	0.16	0.16	0.16	0.08	-0.05	0.24	0.27	0.37	-0.08	-0.28	-0.33	0.33	0.25	-0.46	0.16	-0.08	0.06		-0.11	-0.21
Reconciled Depreciation	0.9	0.36	0.78	0.86	0.92	-0.49	-0.36	-0.32	-0.64	0.9	-0.43	-0.39	0.43	0.26	0.91	0.75	-0.61	-0.43	0.79	-0.68	0.24	-0.67	-0.11		0.92
Extraordinary Items	0.85	0.47	0.87	0.95	0.92	-0.32	-0.21	-0.18	-0.71	0.91	-0.23	-0.24	0.28	0.12	0.85	0.9	-0.45	-0.23	0.69	-0.82	0.1	-0.65	-0.21	0.92

Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	16.0M	17.2M	19.6M	22.1M	22.5M	23.6M
Interest Expense	49M	45.0M	4.3M	8.1M	81.5M	85.5M
Total Revenue	1.1B	729M	810M	587M	787.6M	827.0M
Gross Profit	1.1B	717M	799M	573M	778.5M	817.4M
Other Operating Expenses	757M	901M	840M	998M	1.1B	1.2B
Operating Income	366M	(172M)	(30M)	(411M)	(353.7M)	(336.0M)
Ebit	366M	(172M)	(19.8M)	(249.9M)	(252.5M)	(239.9M)
Ebitda	382.0M	(154.8M)	(239K)	(227.8M)	(230.0M)	(218.5M)
Cost Of Revenue	4M	12M	11M	14M	9.1M	8.7M
Total Operating Expenses	753M	889M	829M	984M	779.6M	818.6M
Net Income	294M	(487M)	(29M)	(270M)	(366.3M)	(348.0M)
Income Before Tax	347M	(170M)	(30M)	(258M)	(334.0M)	(317.3M)
Total Other Income Expense Net	(19M)	2M	1.0M	152.2M	19.8M	20.8M
Income Tax Expense	44M	317M	(1M)	12M	32.3M	33.9M
Research Development	466M	535M	643M	833M	899.6M	944.6M
Selling General Administrative	287M	354M	170.9M	150.3M	232.6M	244.2M
Net Income From Continuing Ops	303.3M	(486.8M)	(28.6M)	(269.7M)	(366.3M)	(348.0M)
Non Operating Income Net Other	29.7M	47.0M	10.4M	160.3M	184.4M	193.6M
Net Income Applicable To Common Shares	294.1M	(451.3M)	(28.6M)	(269.7M)	(242.7M)	(230.6M)
Minority Interest	(11.3M)	(58.8M)	9.1M	(35.5M)	1.2M	0.0
Tax Provision	43.5M	317M	(1M)	11.7M	32.3M	33.9M
Net Interest Income	(48.8M)	(45.0M)	(9.2M)	(8.1M)	(81.5M)	(77.4M)
Reconciled Depreciation	16.0M	17.2M	19.6M	22.1M	22.5M	18.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ionis Historical Income Statement

About Ionis Income Statement Analysis

Ionis Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Cost Of Revenue

Total Operating Expenses

Ionis Pharmaceuticals income statement Correlations

Ionis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ionis Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Ionis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Tax Provision	+ 1.0	Income Tax Expense
Income Before Tax	+ 0.99	Ebit
Income Before Tax	+ 0.99	Ebitda
Research Development	+ 0.98	Other Operating Expenses

Minority Interest	- 0.88	Selling General Administrative
Net Interest Income	- 0.88	Interest Expense
Non Operating Income Net Other	- 0.86	Selling And Marketing Expenses
Minority Interest	- 0.84	Total Operating Expenses
Extraordinary Items	- 0.82	Minority Interest
Minority Interest	- 0.78	Other Operating Expenses